TRACON Pharmaceuticals (NASDAQ:TCON) is scheduled to be announcing its earnings results after the market closes on Monday, February 26th. Analysts expect the company to announce earnings of ($0.46) per share for the quarter.
Shares of TRACON Pharmaceuticals (NASDAQ:TCON) opened at $2.20 on Monday. The company has a debt-to-equity ratio of 0.24, a quick ratio of 3.80 and a current ratio of 3.80. The firm has a market capitalization of $38.53, a PE ratio of -1.80 and a beta of 2.06. TRACON Pharmaceuticals has a 52 week low of $2.00 and a 52 week high of $4.70.
Separately, Zacks Investment Research upgraded TRACON Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.25 target price for the company in a research note on Saturday, November 11th.
WARNING: “TRACON Pharmaceuticals (TCON) Scheduled to Post Earnings on Monday” was originally reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at https://www.chaffeybreeze.com/2018/02/19/tracon-pharmaceuticals-tcon-scheduled-to-post-earnings-on-monday.html.
TRACON Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company’s research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring).
Receive News & Ratings for TRACON Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.